Table 1.
Baseline Characteristics and Other Characteristics of Participants
| Baseline Characteristics | Control Group (n = 23) | Intervention Group(n = 23) | 95% CI |
|---|---|---|---|
| LVEF, % | 25.4 (1.8) | 26.3 (1.8) | −6.1 to 4.3 |
| AHI, events/h | 33 (3.0) | 36 (2.0) | −11 to 5 |
| BNP level | 1,154 (261)* | 1,117 (259)† | −708 to 780 |
| SBP, mm Hg | 110 (4.0) | 107 (4.0) | −8 to 14 |
| DBP, mm Hg | 67 (2.0) | 66 (2.0) | −5 to 8 |
| Heart rate,beats/min | 88 (4.0) | 81 (3.0) | −3 to 17 |
| Creatinine level | 1.3 (0.08) | 1.4 (0.13) | −0.4 to 0.2 |
| LVEDD, mm | 62 (2.0)† | 64 (2.0)* | −8 to 2 |
| LVEDV, mL | 227 (18)‡ | 235 (20)§ | −63 to 47 |
| LVESD, mm | 54 (2)† | 56 (2)‡ | −8 to 4 |
| LVESV, mL | 169 (15)‡ | 171 (17)§ | −48 to 44 |
| Other characteristics | |||
| Age, yr | 58 (3.0) | 55 (3.0) | −5 to 11 |
| BMI, kg/m2 | 32 (2.0) | 35 (3.0) | −10 to 3 |
| Male gender, % | 83 (8.0) | 65 (10) | −9 to 44 |
| Ischemic cardiomyopathy, % | 78 (9.0) | 87 (7.0) | −32 to 14 |
| Receivingβ-blocker therapy (carvedilol/metoprolol), % | 83 (8.0) | 74 (9.0) | −16 to 34 |
| Receiving angiotensin-converting enzyme inhibitor therapy, % | 65 (10) | 48 (11) | −12 to 47 |
| Diabetes, % | 54 (11) | 61 (10) | −41 to 20 |
Values are given as the mean (SE), unless otherwise indicated. DBP = diastolic BP; LVEDD = left ventricular end-diastolic diameter; LVESD = left ventricular end systolic diameter; SBP = systolic BP.
*n = 20 (No. is smaller than the group size because of missing values).
†n = 22 (No. is smaller than the group size because of missing values).
‡n = 19 (No. is smaller than the group size because of missing values).
§n = 17 (No. is smaller than the group size because of missing values).